About Juvena Therapeutics. Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to develop disease-modifying biologics to treat chronic muscle and metabolic diseases.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones. | Eli Lilly is beefing up muscle health ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by JuvenaCollaboration aims to accelerate the ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform ...

REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform, an AI ...